Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Inventory (2016 - 2018)

Historic Inventory for Theravance Biopharma (TBPH) over the last 6 years, with Q3 2018 value amounting to $17.9 million.

  • Theravance Biopharma's Inventory rose 1746.62% to $17.9 million in Q3 2018 from the same period last year, while for Sep 2018 it was $17.9 million, marking a year-over-year increase of 1746.62%. This contributed to the annual value of $16.8 million for FY2017, which is 3772.5% up from last year.
  • Latest data reveals that Theravance Biopharma reported Inventory of $17.9 million as of Q3 2018, which was up 1746.62% from $17.9 million recorded in Q2 2018.
  • Theravance Biopharma's 5-year Inventory high stood at $17.9 million for Q3 2018, and its period low was $9.4 million during Q1 2016.
  • Over the past 5 years, Theravance Biopharma's median Inventory value was $12.5 million (recorded in 2014), while the average stood at $13.4 million.
  • As far as peak fluctuations go, Theravance Biopharma's Inventory plummeted by 2375.78% in 2016, and later surged by 4766.62% in 2018.
  • Over the past 5 years, Theravance Biopharma's Inventory (Quarter) stood at $12.5 million in 2014, then decreased by 20.25% to $10.0 million in 2015, then grew by 22.14% to $12.2 million in 2016, then soared by 37.73% to $16.8 million in 2017, then grew by 6.49% to $17.9 million in 2018.
  • Its Inventory stands at $17.9 million for Q3 2018, versus $17.9 million for Q2 2018 and $17.2 million for Q1 2018.